During iDR25 – the international drug repurposing conference organized by REMEDi4ALL – RARE-NL will be prominently represented. In various sessions, we’ll share our insights and experiences on the reuse of existing medicines for new indications (drug repurposing).

On Friday, May 9, Saco de Visser, Sibren van den Berg, and Vincent van der Wel will participate in the session “Strategies for Creating a Sustainable Business Model for Drug Repurposing.”
Although drug repurposing holds immense potential to deliver affordable, effective treatments to patients more quickly, this potential often remains untapped due to the lack of a solid business case. That’s why RARE-NL advocates for new models that generate both economic and societal value. Only then can we ensure that existing treatments truly become available to those who need them—such as patients with rare diseases.

Interested? This recent article in Drug Discovery Today explores the challenges and solutions surrounding the sustainable valorization of repurposed medicines:Reliable business case for repurposing of existing medicines requires key changes in government policies – ScienceDirect